Cilan

Quick links to important sections

Cilan

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cilan

Quick Facts

Property Description
Active Ingredient Cilazapril
Form Oral tablet (film-coated)
Pharmacological Class Angiotensin-Converting Enzyme (ACE) Inhibitor
General Purpose To lower systemic blood pressure
Origin Synthetic compound

What Type of Medicine is Cilan?

Cilan is a synthetic pharmaceutical preparation defined by its active ingredient, Cilazapril. It belongs to the established Angiotensin-Converting Enzyme (ACE) inhibitor class, positioning it as a key type of cardiovascular drug. This classification means Cilan’s function is to interrupt a specific biological process responsible for regulating blood pressure. This class of medicine is designed to block substances that narrow blood vessels, a mechanism clinically recognized for its long-term efficacy in managing hypertension. As a sophisticated, single-component medicine derived from controlled processes, its identity is fully characterized by its established mechanism, distinguishing it from herbal or multi-component preparations.


Composition and Form of Cilan

The primary component of Cilan is Cilazapril, which is presented for oral administration as a film-coated tablet. Cilazapril exists chemically as the dihydrate form within the tablet structure. Cilazapril is classified as a pro-drug. This classification means your body transforms the medicine into its highly potent active form after you take it. The choice of a solid oral dosage form confirms its intended systemic action, requiring the drug to be absorbed into the bloodstream to reach its therapeutic targets. Cilazapril is also known under the trade names Inhibace and Vascase in various markets, sharing the same core mechanism and synthetic origin.


What is the General Purpose of Cilan?

The general therapeutic objective of Cilan is the sustained lowering of high blood pressure (systemic hypertension), a typical use scenario for adult patients with cardiovascular conditions. This purpose is achieved through the drug's action as a RAAS modulator. By reducing the activity of the Renin-Angiotensin-Aldosterone System, Cilan lessens the tension in blood vessel walls, promoting vasodilation, and helps decrease the body's tendency to retain excess salt and fluid. This foundational action contributes directly to reducing the overall strain on the cardiovascular system.

Regulatory References

  1. ACE inhibitors: MedlinePlus Medical Encyclopedia

What side effects are possible with Cilan?

Possible Side Effects and Safety Information

The safety profile of Cilan (Cilazapril), an Angiotensin-Converting Enzyme (ACE) inhibitor, is officially documented by regulatory authorities, with adverse reactions categorized by frequency and the body system affected. These classifications establish the known risks associated with the medication.


Frequency and System-Organ Classifications

Classification Tier Documented Adverse Reactions (Examples)
Common Headache, dizziness, and a characteristic dry cough are frequently reported adverse reactions.
Uncommon / Rare Effects such as fatigue, nausea, vomiting, diarrhea, syncope (fainting), and abnormalities in liver and kidney function are officially listed.

Serious Adverse Reactions and Safety Restrictions

Regulatory documents highlight specific serious adverse reactions. The most clinically significant is angioedema, a potentially life-threatening swelling of the face, tongue, or throat. Severe hypotension (excessively low blood pressure) and acute renal failure are also documented as serious risks.

Safety is also defined by explicit constraints for certain populations and conditions. Cilazapril is contraindicated during pregnancy, particularly in the second and third trimesters, due to the risk of fetal injury. Specific safety considerations apply to elderly patients and individuals with renal impairment or liver cirrhosis.

Time-related patterns note that first-dose hypotension is a possibility, and angioedema can occur at any time during treatment. Furthermore, patients with a history of ACE inhibitor-induced angioedema are excluded from using this medicine.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Cilan (Cilazapril) is primarily characterized by severe physiological effects resulting from the drug’s excessive action. The most prominent documented clinical sign is severe hypotension, which may progress to a state of circulatory shock. Other manifestations listed in regulatory documents include disturbances in heart rate, such as bradycardia or tachycardia, along with symptoms like dizziness and hyperventilation. Physiological complications include acute renal failure and serious electrolyte disturbances, specifically hyperkalemia and hyponatremia.

Required Emergency Action

Official regulatory guidance mandates that individuals seek immediate medical attention for any signs of angioedema, particularly swelling of the face, tongue, or throat, as this can result in life-threatening airway obstruction. Contacting a regional poison control centre is also advised in cases of suspected overdose.

Management and Monitoring

Treatment for Cilan overdose is strictly symptomatic and supportive, as no specific antidote is known. Officially described supportive measures include placing the patient in the shock position and initiating intravenous fluid administration to manage severe hypotension. Continuous observation of vital signs, serum electrolytes, and creatinine concentrations is required until stability is confirmed.

Therapeutic Uses of Cilan

Quick Facts About Cilan

  • Therapeutic Domain 1: Management of certain heart rhythm disorders (arrhythmias).
  • Therapeutic Domain 2: Symptomatic relief for chest pain (angina).
  • Therapeutic Domain 3: Treatment of elevated blood pressure (hypertension).

Cilan is a prescription medication utilized in the management of specific cardiovascular conditions. The primary therapeutic domains for Cilan include the sustained treatment of elevated blood pressure, which may assist in lowering the risk of related health events.

The medication is also indicated for the relief of stable or chronic chest pain, commonly known as angina pectoris. Additionally, Cilan plays a role in addressing certain supraventricular heart rhythm disorders, helping to regulate the heart's electrical activity. This usage may contribute to a reduction in the frequency of episodes related to these rhythm disturbances.

Patients should consult a healthcare provider for a comprehensive understanding of how Cilan is used in a specific care plan.

Eligibility and Restrictions for Use

The eligibility profile for Cilan (containing the active ingredient Cilazapril) is defined by contraindications and conditions requiring restricted use, as outlined in official government regulatory documents.

Contraindicated Populations

Cilan must not be used by the following groups, as stated in the product labeling:

  • Patients with a history of angioedema (swelling beneath the skin) related to any previous treatment with an Angiotensin-Converting Enzyme (ACE) inhibitor.
  • Patients with hereditary or idiopathic angioedema.
  • Women who are in the second or third trimesters of pregnancy.
  • Patients taking Sacubitril/Valsartan (used for heart failure), due to a significantly increased risk of angioedema.
  • Patients with anuria (inability to produce urine).

Restricted and Conditional Use

Use is not recommended or requires special consideration for:

  • Pediatrics (Children): Safety and effectiveness in this age group have not been established.
  • Renal Impairment: Reduced dosages are required for patients with impaired kidney function.
  • Liver Impairment: Use requires extreme caution, and a lower starting dose is often necessary, particularly in patients with liver cirrhosis without ascites.
  • Elderly Patients: Clearance of the active substance may be reduced, necessitating careful individual dose adjustments.

Official labeling classifies non-eligibility into absolute exclusions (contraindications) and populations where use is restricted or not established, primarily based on prior adverse reactions, co-administered medications, and physiological or organ status.

What should I know about interactions with other medicines?

Cilan's official regulatory profile details documented interaction patterns primarily focused on pharmacodynamic synergy and specific regulatory restrictions.

Contraindicated Combinations

Co-administration with the neprilysin inhibitor combination Sacubitril/Valsartan is formally contraindicated, requiring a mandatory 36-hour separation period. The use of Aliskiren is contraindicated in patients with diabetes or moderate-to-severe renal impairment (GFR < 60 mL/min/1.73 m^2) because of the heightened risks associated with dual blockade of the Renin-Angiotensin System.

Pharmacodynamic Risk Enhancement

The risk of hyperkalemia (high potassium levels) is elevated when Cilan is co-administered with Potassium-sparing Diuretics (e.g., Spironolactone) or Potassium Supplements. Combining Cilan with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including certain selective agents, increases the documented risk of renal failure and may reduce the antihypertensive effect. Other agents, such as certain mTOR and DPP-IV inhibitors, also increase the risk of angioedema. Co-administration with Lithium may result in increased serum concentrations of lithium.

Other Documented Interaction Constraints

The regulatory label notes a pharmacokinetic interaction where food ingestion reduces the peak plasma concentration ( C max) of the active metabolite, Cilazaprilat. Furthermore, Cilan must be temporarily withheld before certain medical procedures, such as LDL apheresis or desensitization therapy, to mitigate the risk of acute systemic reactions.

Mechanism of Action

Cilan is a non-dihydropyridine calcium channel blocker that functions as an inhibitor of L-type calcium channels (CaV1) in cardiac and vascular smooth muscle cells.

This molecular interaction targets the voltage-gated channels to restrict the inward flow of extracellular calcium ions ( Ca^2+), thereby suppressing the Ca^2+-dependent processes necessary for muscle contraction and electrical conduction.

In the heart, this cascade produces the effects of negative chronotropy (slowing of spontaneous depolarization, particularly in the AV node) and negative inotropy (decreased force of myocardial contraction). Concurrently, Cilan prevents the activation of the excitation-contraction coupling pathway in vascular smooth muscle. This mechanism causes the peripheral arteries to relax and widen (vasodilation), resulting in a decrease in systemic vascular resistance.

Dosage and Administration Information

How to use Cilan

Cilan is available as a film-coated tablet for oral administration. To ensure correct dosing, the tablet must be swallowed whole with water and must not be chewed or crushed. The medicine is typically administered once daily, preferably at the same time each day. Intake is permitted with or without food, as meals do not significantly alter its absorption.


Official Dosing Regimens

The standard adult dosing is structured around the patient’s condition. For the sustained management of elevated blood pressure, the typical starting dose is 1 mg or 2.5 mg once daily, with a maintenance range generally between 2.5 mg to 5 mg. For the initiation of treatment in chronic heart failure, a low starting dose of 0.5 mg once daily is specified, with a maximum dose officially limited to 2.5 mg. Dose adjustments (titration) are generally performed at intervals of at least two weeks to assess patient response.


Contextual and Population Adjustments

Administration of Cilan is modified for specific physiological conditions. For older adults or individuals with moderate renal impairment (CrCl 10 –40 mL/min), the starting dose is often reduced to 0.5 mg. The initial administration of the lowest dose may also require close medical supervision in high-risk patients. Pediatric use is not recommended due to lack of established safety and efficacy data.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cilan (Cilazapril)


Evidence for Use in High Blood Pressure (Essential Hypertension)

A body of research exists for Cilan, including numerous Randomized Controlled Trials (RCTs). Researchers primarily studied Cilan over short-to-medium-term periods, generally ranging from a few weeks up to several months. The main outcomes monitoring physiological strain were measured changes in both systolic and diastolic blood pressure, which are standard clinical measurements used in these trials.

Findings describe patterns observed in the studies where Cilan was associated with changes in blood pressure readings, and researchers reported measurements monitored across the defined time intervals. However, some of the initial RCTs used sample sizes that were modest (small patient cohorts), and the ability to generalize findings to broader populations may be limited. Long-term effects are not fully established specifically for Cilan in large cardiovascular event reduction trials.


Evidence for Use in Chronic Heart Failure

Cilan was studied for its use as an adjunctive treatment for individuals living with chronic heart failure (CHF), which is a condition that was observed in research for Cilan. The research includes controlled clinical trials where Cilan was often compared against a placebo or another ACE inhibitor medicine.

The trials exploring outcomes related to symptoms primarily focused on symptomatic assessment. Researchers reported how symptoms evolved in the observed populations over the monitored time intervals. However, the measured changes in patient-reported quality of life were described as small in magnitude and varied across study participants.


What is Still Uncertain About Cilan Research

While a significant amount of research was studied for Cilan, several areas remain where research could provide greater clarity. The primary area of uncertainty involves the long-term effects of the medicine. While short- and medium-term evidence exists, long-term effects are not fully established through Cilan-specific trials dedicated to major cardiovascular event reduction. Additionally, evidence quality varies across studies, particularly for conditions like stable angina, where initial findings relied on sample sizes that were modest and preliminary trial designs.

Frequently Asked Questions (FAQ)

Common questions about Cilan (FAQ)


Q: How quickly do the effects of Cilan usually begin?

A: Studies and official information indicate that the blood pressure-lowering effect often begins within about one hour after the medicine is taken orally. It may take longer than this initial onset time for the full intended therapeutic effect to develop.

Q: What is the typical timeframe before the full effects of Cilan are noted?

A: Regulatory guidance states that the doctor typically adjusts the dose (titration) at intervals of at least two weeks. This time period allows the healthcare professional to fully assess how the medicine is working before making any further dose changes.

Q: Are there any common foods or drinks that should be avoided while taking Cilan?

A: Official regulatory documents note that alcohol may increase the medicine's blood pressure-lowering effect. Patients are generally advised to discuss the consumption of alcohol with a healthcare professional, as its use with Cilan is documented to result in potential interactions.

Q: Are there known interactions between Cilan and common over-the-counter pain relievers?

A: The official label documents interactions with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include several common over-the-counter pain relievers. Combining Cilan with NSAIDs is noted to increase the documented risk of kidney problems and may potentially reduce the blood pressure effect of Cilan.

Q: Are there any known severe side effects associated with Cilan that require immediate attention?

A: Regulatory documents emphasize that severe adverse reactions such as angioedema, which is a potentially life-threatening swelling of the face, tongue, or throat, require immediate attention. The official product information indicates that the medicine should be immediately discontinued if this reaction occurs, and emergency medical help should be sought.

Q: Does Cilan interact with alcohol?

A: Yes, Cilan is documented to have potential interactions with alcohol. This combination can result in an exaggerated blood pressure-lowering effect, meaning blood pressure might drop excessively.

Q: Does Cilan interact with grapefruit or grapefruit juice?

A: Based on the medicine's clearance and how it is processed by the body, a clinically significant interaction with grapefruit or grapefruit juice is generally considered unlikely in regulatory assessments.

Q: What do official sources say about the use of Cilan in people with heart conditions?

A: Official documents describe Cilan's use for the treatment of high blood pressure (hypertension) and as an adjunctive therapy for individuals with chronic heart failure (CHF).

Q: What is the typical time of onset for side effects from Cilan?

A: The official label notes that low blood pressure (hypotension) is a possibility after the very first dose of the medicine. Other severe reactions, such as angioedema, can potentially occur at any point while taking the medicine.

Q: Does taking Cilan affect the ability to drive or operate machinery?

A: Since Cilan may cause common adverse reactions like dizziness or fatigue, the official information recommends caution. It is suggested that patients avoid driving or operating complex machinery until their response to the medicine is known.

Q: Do people typically need to take Cilan for a long time?

A: Cilan is often prescribed for the sustained management of chronic cardiovascular conditions, such as high blood pressure and chronic heart failure. These conditions typically require ongoing treatment to maintain the desired therapeutic effect.

Q: What should I expect in the first week of starting Cilan?

A: In the first week, patients might experience the onset of blood pressure lowering, which often begins within the first day of taking the dose. Common adverse reactions reported in the first weeks may include experiences such as headache or dizziness.

Q: Does Cilan build up in the body over time?

A: The active form of the medicine has a long terminal half-life of 30 to 50 hours. This suggests it is designed to stay in the system for some time, and it takes several days of consistent daily dosing to reach a steady state where the amount taken balances the amount eliminated.

Q: Can Cilan affect the results of any common lab tests?

A: Regulatory information indicates that Cilan can cause changes in certain lab values. This includes a possible increase in potassium levels in the blood, and the medicine may also affect the results of kidney function tests.

Q: Is it normal to feel a certain way after taking Cilan?

A: Official documents classify several experiences as common adverse reactions that people may feel. These include headache, dizziness, and a characteristic dry cough.

Q: Does Cilan cause weight gain or weight loss?

A: Weight change is not listed as a common or frequent adverse reaction of Cilan in regulatory documents. However, weight loss is noted as a potential sign of serious, rare adverse reactions like liver problems or infection.

Q: What happens if a dose of Cilan is forgotten?

A: If a daily dose is forgotten, general patient guidance is to take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the forgotten dose should be skipped entirely. Official guidance states that a double dose should not be taken to make up for a forgotten dose.

Q: Is Cilan often prescribed alongside other medicines?

A: Yes, regulatory information notes that Cilan is studied and prescribed as an adjunctive therapy for certain conditions, such as chronic heart failure. It is also available in some markets in fixed-dose combination products with other cardiovascular medicines.

Q: Does Cilan have an official classification or schedule number?

A: Official documents classify Cilan based on its mechanism of action. It belongs to the established class of Angiotensin-Converting Enzyme (ACE) Inhibitors, which is a type of medicine used for cardiovascular treatment.

Q: Are there any lifestyle changes that are often suggested when using Cilan?

A: Official warnings note that Cilan must be temporarily withheld before certain specific medical procedures. These procedures include LDL apheresis (a cholesterol removal procedure) or desensitization therapy.

Q: How does Cilan get removed from the body?

A: Cilan is a pro-drug, which means the body converts it into its active form, Cilazaprilat. The active form is then primarily eliminated from the body through the kidneys.

Q: Does Cilan require any special monitoring by a doctor?

A: Yes, the official label requires special patient consideration and monitoring. This includes regular monitoring of potassium levels and kidney function through blood tests to ensure patient safety.

Q: What happens if someone accidentally takes too much Cilan?

A: Taking too much Cilan can cause an exaggerated effect of the medicine. The most prominent effect expected is severe low blood pressure (hypotension), which may require monitoring and supportive measures as determined by a healthcare professional.

Q: Is Cilan known to cause any long-term health issues?

A: Research summaries indicate that while there is short- and medium-term evidence for Cilan, the long-term effects specifically regarding major cardiovascular event reduction are not fully established in dedicated large trials.

Q: Has Cilan been approved in countries outside the US?

A: Yes, Cilan is approved for use in multiple regions globally. The product information is defined by regulatory documents from bodies such as the European Medicines Agency (EMA) and Health Canada.

Q: What is the half-life of Cilan?

A: Pharmacokinetic data reports that the terminal half-life of the active form of the medicine, Cilazaprilat, is between 30 and 50 hours. The half-life describes the time required for the amount of medicine in the body to be reduced by half.

How should Cilan be stored and disposed of?

The storage and disposal of Cilan (Cilazapril) tablets must comply with official regulatory documentation to maintain product quality and public safety.

Official Storage Conditions

Cilan must be stored at controlled room temperature, typically between 15°C and 30°C (59°F and 86°F). The medicine must be kept in a tightly closed container in a dry place, away from direct light and excessive heat. Freezing or refrigerating the product is prohibited by regulatory guidance. To ensure safety, Cilan must be stored out of the sight and reach of children and pets.

Disposal Instructions

The product should not be used after the expiration date printed on the package. Official instructions prohibit flushing Cilan down a toilet or pouring it down a drain unless specifically advised by a healthcare professional. Unused or expired medication must be disposed of according to local pharmaceutical waste regulations, and patients should consult a pharmacist for the proper disposal method.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cilan found in:

A-Z Index: